// App-Quantinova.ai

1599 : Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Researchers

Presenter

  • Joseph Merola

Principal Investigators

  • Robert Landewé

  • Iain B McInnes

  • Philip J Mease

  • Christopher Ritchlin

  • Yoshiya Tanaka

  • Akihiko Asahina

  • Frank Behrens

  • Dafna Gladman

  • Laure Gossec

  • Richard Warren

  • Barbara Ink

  • Deepak Assudani

  • Rajan Bajracharya

  • Jason Coarse

  • Laura Coates

Medical Centers

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • Amsterdam University Medical Center, Overveen, Netherlands

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

  • Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany

  • Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada

  • Sorbonne Universites, Paris, France

  • University of Manchester, Manchester, United Kingdom

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, NC, USA, Raleigh, NC

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

Locations

  • United States

  • Netherlands

  • United Kingdom

  • Japan

  • Germany

  • Canada

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT03896581

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved